Biobank for development of screening markers for colorectal neoplasia. Translational research in colorectal cancer and adenomas.

Biobank for development of screening markers for colorectal neoplasia. Translational research in colorectal cancer and adenomas. - Biobank for development of screening markers for colorectal neoplasia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37786

Enrollment

3500

Registered

2012-07-06

Start date

2012-07-19

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coloncancer. Large polyps.

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All subjects 40 years of age or older scheduled for colonoscopy will be invited to participate. Subjects with colorectalcancer (CRC) or advanced adenomas detected at colonoscopy will be included as cases, whereas subjects without advanced neoplasia will be included as controls. All subjects should be capable to give informed consent. All subjects should speak and understand the Dutch language

Exclusion criteria

Exclusion criteria: - Subjects

Design outcomes

Secondary

Measure	Time frame
Quality and stability of samples collected.	—

Primary

Measure	Time frame
Collection of faeces for development and improvement of new biomarkers for CRC. Development of a stool test with a (panel of) molecular marker(s). Endpoints for evaluation of screening markers: presence of CRC and advanced adenomas (advanced neoplasia). The following test characteristics are used as primary outcome measurements for the different biomarkers. - Sensitivity - Specificity - Positive predictive value (PPV) - Negative predictive value (NPV)	—

Measure

Time frame

Collection of faeces for development and improvement of new biomarkers for CRC. Development of a stool test with a (panel of) molecular marker(s). Endpoints for evaluation of screening markers: presence of CRC and advanced adenomas (advanced neoplasia). The following test characteristics are used as primary outcome measurements for the different biomarkers. - Sensitivity - Specificity - Positive predictive value (PPV) - Negative predictive value (NPV)

—

Countries

Netherlands

Outcome results